Full-Time

Associate Director

Portfolio Reporting & Analytics

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

No salary listed

Senior, Expert

No H1B Sponsorship

Cambridge, MA, USA

70% of time spent in the office

US Citizenship Required

Category
Computational Biology
Public Health
Biology & Biotech
Required Skills
Tableau
Data Analysis
Requirements
  • Bachelor’s, Master’s, or PhD in life and/or computer science disciplines from a top-tier institution
  • 6+ years of experience in data or analytics roles, preferably in biopharma or consulting
  • Expertise in program/project management and/or clinical drug development across all phases
  • Experience developing scalable dashboards and reporting solutions for decision-making
  • Proficiency in data governance, master data management, and managing complex datasets
  • Strong capabilities in data wrangling, modeling, and designing data pipelines
  • Proficiency in data visualization tools such as Tableau, Spotfire, and/or Shiny
  • Proven ability to lead and deliver high-impact, cross-functional projects with limited oversight
Responsibilities
  • Deliver analytics and insights that support portfolio-level decisions across clinical development programs
  • Develop and maintain scalable reporting platforms and dashboards that enable strategic trade-off decisions
  • Manage and analyze complex datasets, applying data wrangling, modeling, and pipeline design techniques
  • Leverage expertise in program and project management or clinical drug development across all phases
  • Utilize tools such as Tableau, Spotfire, and Shiny to visualize portfolio performance and insights
  • Apply data governance and master data management principles to ensure consistency and quality
  • Collaborate with cross-functional stakeholders to gather requirements and translate them into actionable analytics
  • Facilitate workshops and contribute to portfolio road mapping, prioritization, and capability development
  • Additional duties as may be assigned from time to time
Desired Qualifications
  • Excellent verbal and written communication skills with the ability to convey insights to diverse audiences, including executives
  • Creative and versatile problem-solving abilities, balancing emotional intelligence and analytical rigor
  • Strong analytical skills with a focus on validating reporting logic, filters, and metrics
  • Experience translating business requirements into technical deliverables and collaborating on vendor selection
  • Familiarity with planning ecosystems and documentation tools like Smartsheet
  • Ability to operate in ambiguity and pivot based on evolving business needs and data
  • Experience leading change management efforts, including training and communication strategy
  • Commitment to understanding Moderna’s platform technology and approach to medicine development
  • Proactive, collaborative mindset in support of a high-growth, fast-paced environment
  • Experience with modeling and forecasting using Excel and advanced AI techniques
  • Coding skills in Python, R, and/or SQL

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in the process of protein synthesis in cells. Their products work by delivering mRNA into the body, which instructs cells to produce specific proteins that can help prevent or treat diseases. This approach allows for a new way of creating vaccines and therapies that can be tailored to target various health issues. Unlike traditional methods that often rely on live viruses or proteins, Moderna's mRNA technology offers a more flexible and efficient way to develop medicines. The company's goal is to harness the potential of mRNA to create a new class of medicines that can significantly enhance patient care and health outcomes.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's mRNA platform aligns with the growing trend of personalized medicine.
  • Regulatory approvals in Australia and the UK boost Moderna's market presence for RSV vaccines.
  • AI-driven drug discovery and clinical trials could accelerate Moderna's development processes.

What critics are saying

  • Regulatory scrutiny over trial practices could damage Moderna's reputation and operations.
  • The patent lawsuit with Pfizer and BioNTech poses financial and operational risks.
  • Potential delays in vaccine approvals could hinder Moderna's market entry and growth.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has expanded its pipeline beyond COVID-19 to include RSV and flu vaccines.
  • Moderna collaborates with AI platforms like Benchling to enhance research capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

5%
Things of Business
May 7th, 2025
Benchling and Moderna Collaborate on AI-Driven Research

SAN FRANCISCO and BOSTON, May 7, 2025 - Benchling, the R&D platform powering the biotech industry, today announced an expanded collaboration with Moderna.

Parriva
May 6th, 2025
Flesh-Eating Bacteria Surge in California: What You Need to Know

Moderna is reportedly working on a candidate vaccine using similar mRNA technology to its COVID-19 formula, but experts express concern about regulatory delays.

Labiotech
May 2nd, 2025
From Pandemic Spotlight To Post-Covid Crossroads: What Happened To These Biotech Players?

Newsletter Signup - Under Article / In Page"*" indicates required fields In the heat of the COVID-19 crisis, a wave of vaccine companies stepped into the spotlight with unprecedented speed and visibility. Riding a surge of public and private funding, they raced to develop vaccines and therapeutics that could curb a once-in-a-century global emergency. While pharma giants like AstraZeneca and Johnson Johnson also played prominent roles, much of the momentum and risk was carried by smaller biotech players suddenly thrown onto the global stage. For a brief moment, it seemed like these companies might reshape the pharmaceutical landscape for good.Fast forward to 2025, and the picture is far more complex.Some, like Moderna and BioNTech, used the momentum to build expansive pipelines beyond COVID-19, branching into cancer, flu, RSV, and other diseases. Others, however, are now scaling down, pivoting, or fading from view entirely. Just this month, companies including GeoVax, CastleVax, and Vaxart revealed they were told to halt their government-backed work on next-generation COVID vaccines under the Biden-era Project NextGen, casting doubt on the long-term strategic value of these initiatives

Pulmonology Advisor
Apr 30th, 2025
HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine

Moderna is testing a pandemic-focused vaccine for avian influenza A(H5N1).

Slay News
Apr 27th, 2025
Moderna Faces Ban for Bribing Children to Join Covid 'Vaccine' Trials

Moderna could face suspension over the practices deemed "unacceptable" by regulators.